We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
What's in Store for DENTSPLY (XRAY) This Earnings Season?
Read MoreHide Full Article
DENTSPLY SIRONA Inc.’s (XRAY - Free Report) first-quarter 2018 results are scheduled to release on May 7, before the market opens. The company’s CAD/CAM imaging platform is expected to boost results in the quarter to be reported and improvement in other units are tailwinds as well.
In the last reported quarter, DENTSPLY posted adjusted earnings per share (EPS) of 82 cents, beating the Zacks Consensus Estimate by a penny. However, the metric declined 22.4% year over year. Net sales increased to $1,091 million from $996.5 million in the year-ago quarter. Also, the figure surpassed the Zacks Consensus Estimate of $1056.0 million and rose 5.3% at constant-currency (cc) exchange rate.
Currently, the Zacks Consensus Estimate for earnings in the quarter to be reported is pegged at 42 cents per share, reflecting a decline of 14.3% year over year. The Zacks Consensus Estimate for net sales is projected at $944.7 million, showing an improvement of 4.9% year over year.
Let’s delve into major factors that will influence DENTSPLY performance in the quarter to be reported.
What to Expect From DENTSPLY in Q1?
The company’s CAD/CAM unit is likely to drive the top line in the first quarter. The CAD/CAM is a dental imaging platform and a major foundation in global dental markets.
In the last reported quarter, DENTSPLY announced that consistent focus on sales force effectiveness is likely to boost results. At present, there are 30-plus sales force and close to 5,800 people employed globally in sales and sales-support.
In the quarter to be reported, R&D prospects and innovations will be other growth drivers. Recently, the company announced its plan to redirect industry-leading R&D budget toward high-impact projects that provide a better competitive position.
DENTSPLY confirmed that it has undertaken measures to reduce its interest expense by approximately $20 million by 2018 end, which is likely to boost first-quarter 2018 results. Overall, the company has a very low-cost debt structure and ample availability to grow its businesses and make acquisitions.
On Mar 26, DENTSPLY announced a definitive agreement to acquire OraMetrix — a leading industry provider of innovative 3-D technology solutions.The company also offers an advanced, CAD platform developed for dental professionals to deliver consistently predictable orthodontic outcomes. The transaction is expected to be completed by the second quarter of 2018.
DENTSPLY’s overall growth strategy rests on product innovation. The company’s solid internal growth, amid challenging macroeconomic headwinds, is primarily driven by its innovative new products.
What Does our Model Predict?
Despite solid prospects, our quantitative model does not show a beat for DENTSPLY this earnings season.
This is because a stock needs to have a positive Earnings ESPand a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) to be able to beat estimates.
Zacks ESP: The Earnings ESP for DENTSPLY is +2.73%. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Zacks Rank: DENTSPLY carries a Zacks Rank #5 (Strong Sell). Notably, we caution against stocks with a Zacks Rank #4 (Sell) or 5 going into the earnings announcement, especially when the company is seeing negative estimate revisions.
Stocks Worth a Look
Here are a few medical stocks worth considering as they have the right combination of elements to post a beat this earnings season.
Cardinal Health Inc. (CAH - Free Report) has an Earnings ESP of +0.28% and a Zacks Rank #3.
The Cooper Companies, Inc. (COO - Free Report) has an Earnings ESP of +0.26% and a Zacks Rank #3.
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.
Image: Bigstock
What's in Store for DENTSPLY (XRAY) This Earnings Season?
DENTSPLY SIRONA Inc.’s (XRAY - Free Report) first-quarter 2018 results are scheduled to release on May 7, before the market opens. The company’s CAD/CAM imaging platform is expected to boost results in the quarter to be reported and improvement in other units are tailwinds as well.
In the last reported quarter, DENTSPLY posted adjusted earnings per share (EPS) of 82 cents, beating the Zacks Consensus Estimate by a penny. However, the metric declined 22.4% year over year. Net sales increased to $1,091 million from $996.5 million in the year-ago quarter. Also, the figure surpassed the Zacks Consensus Estimate of $1056.0 million and rose 5.3% at constant-currency (cc) exchange rate.
Currently, the Zacks Consensus Estimate for earnings in the quarter to be reported is pegged at 42 cents per share, reflecting a decline of 14.3% year over year. The Zacks Consensus Estimate for net sales is projected at $944.7 million, showing an improvement of 4.9% year over year.
Let’s delve into major factors that will influence DENTSPLY performance in the quarter to be reported.
What to Expect From DENTSPLY in Q1?
The company’s CAD/CAM unit is likely to drive the top line in the first quarter. The CAD/CAM is a dental imaging platform and a major foundation in global dental markets.
In the last reported quarter, DENTSPLY announced that consistent focus on sales force effectiveness is likely to boost results. At present, there are 30-plus sales force and close to 5,800 people employed globally in sales and sales-support.
In the quarter to be reported, R&D prospects and innovations will be other growth drivers. Recently, the company announced its plan to redirect industry-leading R&D budget toward high-impact projects that provide a better competitive position.
DENTSPLY SIRONA Inc. Price and EPS Surprise
DENTSPLY SIRONA Inc. Price and EPS Surprise | DENTSPLY SIRONA Inc. Quote
DENTSPLY confirmed that it has undertaken measures to reduce its interest expense by approximately $20 million by 2018 end, which is likely to boost first-quarter 2018 results. Overall, the company has a very low-cost debt structure and ample availability to grow its businesses and make acquisitions.
On Mar 26, DENTSPLY announced a definitive agreement to acquire OraMetrix — a leading industry provider of innovative 3-D technology solutions.The company also offers an advanced, CAD platform developed for dental professionals to deliver consistently predictable orthodontic outcomes. The transaction is expected to be completed by the second quarter of 2018.
DENTSPLY’s overall growth strategy rests on product innovation. The company’s solid internal growth, amid challenging macroeconomic headwinds, is primarily driven by its innovative new products.
What Does our Model Predict?
Despite solid prospects, our quantitative model does not show a beat for DENTSPLY this earnings season.
This is because a stock needs to have a positive Earnings ESPand a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) to be able to beat estimates.
Zacks ESP: The Earnings ESP for DENTSPLY is +2.73%. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Zacks Rank: DENTSPLY carries a Zacks Rank #5 (Strong Sell). Notably, we caution against stocks with a Zacks Rank #4 (Sell) or 5 going into the earnings announcement, especially when the company is seeing negative estimate revisions.
Stocks Worth a Look
Here are a few medical stocks worth considering as they have the right combination of elements to post a beat this earnings season.
Becton, Dickinson and Company (BDX - Free Report) has an Earnings ESP of +0.61% and a Zacks Rank #3. You can see the complete list of today’s Zacks #1 Rank stocks here.
Cardinal Health Inc. (CAH - Free Report) has an Earnings ESP of +0.28% and a Zacks Rank #3.
The Cooper Companies, Inc. (COO - Free Report) has an Earnings ESP of +0.26% and a Zacks Rank #3.
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.
See the pot trades we're targeting>>